Loading…
← CockpitCompetitor Analysis › 3705.TW YungShin Global Holding Corp.Open in the cockpit ↗

YungShin Global Holding Corp.3705.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum leader 84
Mkt cap
$472M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$442,197
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+5.7 pp
WACC 5.0%
Hurdle
-5 pp
Req g minus delivered
Close · TWDNT$58.90
1D+0.5%
1W+1.4%
1M-5.0%
3M+8.5%
6M+5.0%
YTD+3.3%
1Y+4.8%
ATR %2.0%
52w lowhigh5.0% off high

What YungShin Global does

No business profile yet.

YungShin Global at a glance

Size YungShin Global (3705.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $472M, the 449th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$58.90 on 18 Nov 2026.

Performance Over six months the shares gained 5.0%, against -14.7% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue fell 5.1% over the last twelve months (peer median +12.5%); the operating margin is 15.1% (peer median 2.5%).

Valuation It trades at 2.0× enterprise value to sales against a peer median of 4.9× (3rd cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.7 points above its cost of capital (5.0% WACC).

Relative performance

9010011021 May 202621 Aug 202618 Nov 20263705.TW 105Peer median 84
Six months, rebased to 100: YungShin Global against the median of its 20 peers (local-currency closes).

YungShin Global financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$7.94BNT$8.38BNT$8.03BNT$7.03BNT$7.31B
Revenue growth—+4%+14%-4%—
Gross profitNT$3.41BNT$3.58BNT$3.46BNT$2.91BNT$3.06B
EBITDANT$1.48BNT$1.61BNT$1.59BNT$1.22BNT$1.13B
Net incomeNT$950MNT$881MNT$1.17BNT$827MNT$839M
Free cash flowNT$592MNT$1.01BNT$1.14BNT$1.09BNT$820M
Capital expenditureNT$511MNT$516MNT$241MNT$125MNT$151M
Total debtNT$1.44BNT$1.19BNT$1.23BNT$1.24BNT$1.83B

Quarterly statements and history in the cockpit →

YungShin Global competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%301201AQST6620EOLS002370SMSPHARMACAPRKPL600624HNSA002693RGNX6883730030203005843012773705.TW6-month return →1-month return →
Up and to the right = strong over both horizons. YungShin Global is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%0×10×20×301201AQST6620EOLS002370SMSPHARMAKPL600624HNSA002693RGNX688373003020ASMB30058430127716663705.TWRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. YungShin Global is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%6620HNSA00269330058430127716660021073705.TWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. YungShin Global is the large dot.

YungShin Global competitors and peer comparison

How YungShin Global compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

YungShin Global against its 20 peers (data as of 18 Nov 2026)
Measure3705.TWPeer medianRank in peer set
1-month return-5.0%-2.6%9th lowest of 21
6-month return+5.0%-14.7%7th highest of 20
Distance from 52-week high-5.0%-39.3%2nd highest of 21
Revenue growth (TTM)-5.1%+12.5%5th lowest of 20
Operating margin15.1%2.5%6th highest of 19
EV / Sales2.0×4.9×3rd cheapest of 19
Growth the price implies (Req g, 7 yrs)-3.8%5.9%3rd least demanding of 8
Growth delivered (Del g)+0.7%+6.3%3rd lowest of 8
Hurdle (Req g minus delivered)-4.6 pp-0.2 pp4th least demanding of 8
ROIC minus cost of capital+5.7 pp-5.4 pp3rd highest of 17
EV / EBITDA10.6×24.8×2nd cheapest of 4
Net debt / EBITDA-0.5×0.9×2nd least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%10.8×44.1%+1.0%
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%2.2×n/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%

Questions

Which companies are YungShin Global's closest peers?
The cockpit's peer set: ChengDa PharmaCeuticals (301201.SZ), Aquestive Therapeutics (AQST), Handa Pharmaceuticals (6620.TWO), Evolus (EOLS), Zhejiang Yatai Pharmaceutical (002370.SZ), SMS Pharmaceuticals (SMSPHARMA.NS), Capricor Therapeutics (CAPR), Kwality Pharmaceuticals (KPL.NS).
Is YungShin Global expensive compared with its peers?
On ev / sales it trades at 2.0× against a peer median of 4.9×, 3rd cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has YungShin Global stock performed?
Over six months to 18 Nov 2026 the shares returned +5.0% against -14.7% for the median peer; over one year +4.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.